All In Biotech

NDA 215025 · Maia Pharms INC

Sodium Phenylacetate and Sodium Benzoate

Sodium Benzoate, Sodium Phenylacetate · Intravenous

Last checked: Nov 20, 2026Latest source record: Jun 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jun 10, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,672

341 Phase 3, 113 recruiting

FAERS reports

9

7 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 9, 2024.

Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle.

Mechanism: Urea cycle disorders can result from decreased activity of any of the following enzymes: N -acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG). Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 2 is a schematic illustrating how the components of Sodium Phenylacetate and Sodium Benzoate Injection, phenylacetate and benzoate, provide an alternative...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 10, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • SODIUM PHENYLACETATE AND SODIUM BENZOATE · SODIUM BENZOATE 10%; SODIUM PHENYLACETATE 10% (2GM/20ML · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Benzoate" as an intervention, any sponsor and status, largest first.

All 1,672 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5
  • hyperglycaemia2
  • ammonia decreased1
  • anion gap increased1
  • blood lactic acid increased1
  • brain oedema1
  • cerebral infarction1
  • drug ineffective for unapproved indication1
  • maternal exposure during pregnancy1
  • mycoplasma test positive1
  • off label use1
  • therapy non-responder1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20183
20211
20223
20241
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 283 on PubMed

Sponsor: Maia Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.